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Abstract 
MUC1 is a large, heavily glycosylated transmembrane glycoprotein that is proposed to create 
a protective microenvironment in many adenocarcinomas. Here we compare MUC1 and the 
well studied cell surface receptor target, EGFR, as gold nanoparticle (AuNP) targets and their 
subsequent vapor nanobubble generation efficacy in the human epithelial cell line, HES. Alt-
hough EGFR and MUC1 were both highly expressed in these cells, TEM and confocal images 
revealed MUC1 as a superior target for nanoparticle intracellular accumulation and clustering. 
The MUC1-targeted AuNP intracellular clusters also generated significantly larger vapor 
nanobubbles. Our results demonstrate the promising opportunities MUC1 offers to improve 
the efficacy of targeted nanoparticle based approaches. 
Key words: MUC1, EGFR, Targeted Gold Nanoparticle, Vapor Nanobubble, Nanoparticle Endo-
cytosis, Nanoparticle Clustering. 
Introduction 
Transmembrane mucin glycoproteins perform 
important barrier functions in mucosal epithelia. 
Their large size, heavy O- and N-linked glycosylation, 
and concentration at the apical cell surface make these 
molecules highly effective in this aspect of normal cell 
physiology. MUC1 is a well-studied mucin expressed 
by epithelial tissues of the stomach, pancreas, lung, 
trachea, kidney, salivary and mammary glands, and 
the female reproductive tract (1-3). MUC1’s barrier 
functionality is exploited by many carcinomas as it is 
both overexpressed and distributed over the entire 
cell surface creating a local microenvironment, which 
protects these depolarized cancer cells from the host 
immune system and promotes metastatic activity 
(4-8). The ectodomain of MUC1 extends 200-500 nm 
from the cell surface and contains a tandem repeat 
motif of 20 amino acids rich in serine, threonine, and 
proline (9, 10). Moreover, the steric and charged 
properties of this mucin barrier inhibits the uptake of 
many hydrophobic chemotherapeutic drugs (8, 11, 
12), preferentially protecting cells within a tumor ex-
pressing high levels of MUC1 from antitumor treat-
ments.  
Due to its large size, accessibility, and abundant 
expression in many adenocarcinomas, MUC1 has 
been investigated as a potential target for directed 
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therapies (reviewed in (13)). Antibodies recognizing 
the tandem repeat sequence in the large ectodomain 
have been conjugated to isotopes and drugs for tar-
geted delivery (14-16). More recently, MUC1 has been 
used as a target for nanotherapies. Quantum dots 
conjugated to an aptamer recognizing MUC1 selec-
tively accumulated in tumors in mice versus their 
non-targeted counterparts (17). In another study, 
AuNPs labeled with a MUC1 antibody, PAM4, were 
exposed to radiofrequency radiation in a pancreatic 
cancer mouse model. This allowed for cancer cells, 
which had a higher uptake of the AuNPs than the 
healthy cells, to be destroyed upon irradiation (18). 
MUC1 has also been used in a combination targeting 
approach where a single domain antibody to MUC1 
was conjugated to a polymer nanocarrier containing a 
lethal transgene regulated by a MUC1 promoter in 
vitro (19). A MUC1 aptamer conjugated to paclitaxel 
loaded polymer nanoparticles showed higher uptake 
of the drug to MUC1 expressing cultured cells (20). 
Unlike other targeted nanotherapies, which rely on 
the targeting agent to remain intact through delivery 
via the vasculature system, MUC1 is found in the ep-
ithelial cells and, in many cases, localized, topical de-
livery can be implemented to facilitate efficiency of 
the targeting agent. In addition, the large size and 
accessibility at the cell surface, coupled with the oc-
currence of tandem repeat regions yields the potential 
of a single MUC1 molecule to bind multiple nanopar-
ticles, amplifying the targeting signal.  
The use of AuNPs for cancer therapies has be-
come widespread in recent years due to their diag-
nostic and therapeutic potential determined by size, 
remarkable optical properties, low toxicity, and sur-
face chemistry which allows them to be readily modi-
fied with targeting agents (antibodies, aptamers) to 
direct their delivery. AuNPs have been used as carri-
ers for contrast agents, drugs and siRNAs (21, 22). 
AuNPs have the ability to scatter and absorb visible 
and near infrared light and have been investigated as 
both imaging (23, 24) and therapeutic tools (25) in 
biomedical applications. However, background scat-
tering by cells and tissues often interferes and can 
result in low sensitivity. The photothermal effects of  
AuNPs have been utilized in therapeutic techniques 
such as hyperthermia (26, 27); however, these treat-
ments take up to minutes to achieve results and can 
damage adjacent normal tissues. 
Employing the photothermal properties of gold, 
combined with MUC1 and similar mucins may im-
prove the localized efficacy of MUC1-based diagnos-
tics and therapeutics. Here we show that AuNPs 
conjugated to a MUC1 antibody recognizing the tan-
dem repeat regions in the ectodomain are efficiently 
and specifically delivered to MUC1 expressing cells 
where they form large intracellular clusters. These 
clusters are detected with the photothermal method 
based upon short-pulsed laser excitation of AuNPs 
and subsequent generation of transient vapor nano-
bubbles (28-31). This approach allows detection of 
AuNPs in single cells with high sensitivity. We have 
compared our MUC1 targeted results with another 
well studied cell surface receptor target, EGFR, and 
have found that MUC1 is a superior target for AuNP 
targeting in the human epithelial cell line, HES.  
Methods 
Cell culture 
HES cells were kindly provided by Dr. Doug 
Kniss (Ohio State University, Columbus, OH) and 
HS-5 (CRL-11882) cells were obtained from American 
Type Culture Collection (atcc.org, Manassas, VA). 
HES and HS-5 cells were maintained at 37° C in an 
atmosphere of air/CO2 [95:5 (v/v)]. HES cells were 
supplemented in high glucose DMEM (Gibco Life 
Technologies, Grand Island, NY), supplemented with 
5% (v/v) fetal bovine serum (FBS; Atlanta Biologicals, 
Lawrenceville, GA), and 1 mM sodium pyruvate 
(Sigma, St. Louis, MO). HS-5 cells were maintained in 
low glucose DMEM (Gibco Life Technologies, Grand 
Island, NY), supplemented with 10% (v/v) FBS (At-
lanta Biologicals, Lawrenceville, GA). For experi-
ments, cells were grown as individual or co-cultures 
on removable 2-well Lab-TekTM II Chambered 
SlidesTM (Nunc, Rochester, NY). 
Western Blots 
Cell lysates were solubilized in sample extrac-
tion buffer: 8 M urea; 1% (w/v) SDS; 50 mM Tris, pH 
7.0; 1% (v/v) -mercaptoethanol; and a 1:100 dilution 
of protease inhibitor cocktail (Sigma, St. Louis, MO). 
Protein extracts were incubated for 5 min at 100ºC 
with Laemmli sample buffer (32) and separated by 
SDS-PAGE using a 10% (w/v) Porzio and Pearson 
SDS-PAGE gel (33). Proteins were transferred from 
gels to Trans Blot Transfer Medium nitrocellulose 
membranes (Bio-Rad Laboratories, Hercules, CA) at 
4° C for 5 h at 40 V. Blots were blocked at room tem-
perature for 6-8 h in PBS plus 0.1% (v/v) Tween-20 
(PBS-T) and 3% (w/v) bovine serum albumin (BSA). 
Blots were probed overnight at 4° C (constant rotary 
agitation) with primary antibodies specific for: MUC1 
ectodomain (214D4, kindly provided as hybridoma 
media by Dr. John Hilkens, The Netherlands Cancer 
Institute, Amsterdam, The Netherlands (34)) at a di-
lution of 1:1,000; a rabbit polyclonal antibody that 
recognizes all cell-assoiciated MUC1 (35), CT-1 (at a 
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dilution of 1:2,500; EGFR mouse monoclonal antibody 
clone H9B4 (Invitrogen Life Technologies, Grand Is-
land, NY) at a dilution of 1:5,000, and -actin mouse 
monoclonal antibody clone 8226 (Abcam, Cambridge, 
MA) at a dilution of 1:10,000. Blots were rinsed (3 x 5 
min) at room temperature with PBS-T. Subsequently, 
blots were incubated for 2 h at 4° C with peroxidase 
conjugated a secondary antibody, either sheep an-
ti-mouse or goat anti-rabbit (Jackson Immu-
noresearch, West Grove, PA) at final dilutions of 
1:100,00 and 1:200,000 respectively, in 3% (w/v) 
BSA/PBS-T. Finally, the blots were rinsed three times 
with PBS for (3 x 5 min) at room temperature, and 
antibody binding was detected using the SuperSignal 
West Dura Extended Duration Substrate ECL system 
(Pierce, Rockford, IL) as described by the manufac-
turer. Blots then were exposed to x-ray film and ana-
lyzed by densitometry. 
Preparation of AuNPs 
Gold colloidal nanoparticles (AuNPs; 60 nm) 
and antibody conjugation were prepared commer-
cially (BioAssay Works, Ijamsville, MD) at concentra-
tions of 50 OD. AuNPs were sterile filtered (0.22 m) 
and stored in 0.1X PBS and 0.1% (w/v) BSA for up to 
3 months. The antibodies, 214D4 (Millipore) and C225 
(Cetuximab), were conjugated directly to the surface 
of the AuNPs, taking advantage of dative bonding 
between cysteine thiol groups of the antibody and the 
gold surface. An approximate ratio of 340 to 1 (anti-
body to AuNP) was used in the highly reproducible 
conjugation reaction and resulted in antibody-AuNP 
conjugates with an average hydrodynamic radius of 
the 84.6 nm (+/- 5.5 nm), as measured by dynamic 
light scattering. Prior to incubation with cells, AuNPs 
were diluted in phenol red free media, and their con-
centration adjusted at A548 to 0.22 OD. In experiments 
where both 214D4-AuNPs and C225-AuNPs were 
used in simultaneous incubations, the final concen-
tration at A548 was approximately 0.44 OD. 
AuNP Incubation 
After reaching 50-70% confluency, cells were 
washed three times with serum free DMEM to remove 
cell debris and soluble MUC1. Cells then were incu-
bated with targeted AuNPs at 37° C on an orbital 
rocker for either 1 or 12 hours. Following incubation, 
cells were again washed three times with serum free, 
phenol red free DMEM (Gibco Life Technologies, 
Grand Island, NY) to remove unbound AuNPs. Slide 
chambers were removed and cells were covered with 
a #1.5 coverslip and sealed. 
Transmission Electron Microscopy 
Cells were grown on Permanox® petri dishes and 
fixed with 2% (w/v) glutaraldehyde and 2% (w/v) 
paraformaldehyde in 0.1 M sodium cacodylate buffer 
(pH 7.4) for 1 h at room temperature, then washed in 
0.1 M sodium cacodylate buffer (pH 7.4). Cells were 
placed into fresh 2% (w/v) glutaraldehyde and 2% 
(w/v) paraformaldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.4) and stored at 4° C. Samples were 
washed with 0.1 M sodium cacodylate buffer (pH 7.4) 
and then postfixed in 1% (w/v) osmium tetroxide in 
buffer for 2 h. Cells were washed, dehydrated in an 
ascending acetone series, gradually infiltrated with 
Embed-812 resin (Electron Microscopy Sciences, 
emsdiasum.com) and then polymerized at 60° C for 48 
h. Ultrathin sections were cut on a Reichert-Jung Ul-
tracutE ultramicrotome and collected onto 200 mesh 
formvar-carbon coated copper grids. Sections were 
post-stained with saturated methanolic uranyl acetate 
and Reynolds’ lead citrate and imaged at Delaware 
Biotechnology Institute (Newark, DE) on a Zeiss Libra 
120 transmission electron microscope operated at 120 
kV. Digital images were captured with a Gatan Ul-
trascan 1000 2k x 2k CCD camera. The diameters of 
the AuNP clusters in TEM images were determined 
using the line tool in ImageJ (imagej.nih.gov, v1.45i). 
Scale was set using the 200 or 500 nm scale bar in each 
image, then the diameter between the two furthest 
points along the perimeter of the particle cluster was 
measured. Two-tailed Student T-test used for statis-
tical analysis. 
Confocal Microscopy 
Clustered AuNPs in targeted and non-targeted 
cells were evaluated using confocal microscopy 
(Zeiss, LSM710) Z-stack images in optical scattering 
mode and a 63x oil immersion objective. For quanti-
tative measurements, optical slice images (1 m thick 
and taken at 2.5, 5.0, and 7.5 m from the apical cell 
surface) were analyzed using ImageJ (imagej.nih.gov, 
v1.45i). Dimensionality was reduced to remove 
channels used for cell location and orientation. Back-
ground was subtracted using a rolling ball radius of 
50 for each image and the lower threshold was set to 
~3000, clipping less intense pixels from the analysis. 
Maximum pixel values for each cluster were then 
measured using the analyze particle tool (particles 
were defined by at least 2 pixels). The pixel amplitude 
of reflected scattered light from the AuNP clusters 
correlates to its size (36). Two-level nested analysis of 
variance (ANOVA) was used for statistical analysis. 
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Generation and detection of vapor nanobub-
bles around AuNP clusters 
To image and quantify the uptake of AuNPs by 
cells, we used the vapor bubbles generated around the 
clusters of AuNPs. Recently we demonstrated that 
vapor nanobubbles are triggered by the short-pulsed 
optical heating of AuNPs and has a threshold of gen-
eration that is sensitive to multiple variables including 
clustering of AuNPs (28-31, 37-39). Optical generation 
and detection of vapor nanobubbles were performed 
using a photothermal laser microscope (40, 41). A 532 
nm laser (STH-01, Standa Ltd, Vilnius, Lithuania) was 
used to irradiate single cells with a pulse duration of 
500 ps and a beam diameter of 15 m. A laser pulse 
fluence was experimentally determined for each ex-
periment to exceed the vapor nanobubble generation 
threshold in target cells (HES) and to be below the 
generation threshold for non-target cells. The fluence 
of each laser pulse was measured by registering its 
image and measuring of the beam diameter (at the 
level of 0.5 relative to the maximal intensity in the 
center of the beam) at the sample plane with the im-
aging device (Luka, Andor Technology, Belfast, 
Northern Ireland) and by measuring of the pulse en-
ergy using a pulse energy meter (Ophir Optronics, 
Ltd., Jerusalem, Israel). This scheme provided direct 
and precise measurements of the incident optical 
fluence at the cell plane for each excitation pulse. 
Custom software modules run on a PC and developed 
using the LabView platform was used to operate all 
hardware. 
The superior optical scattering properties of va-
por nanobubbles (28-31, 37-39) were used for their 
detection in individual cells with two probe laser 
beams, a pulsed probe beam (576 nm, 70 ps, 0.1 
mJ/cm2) and a continuous probe laser (633 nm). This 
provided two independent signals: optical scattering 
time-resolved image pixel amplitude and duration of 
optical scattering time response (measured inde-
pendently and simultaneously with the optical scat-
tering image). Time-resolved optical scattering was 
used for imaging of the vapor nanobubbles while, the 
bubble specific time response was independently ob-
tained from the continuous probe laser. The vapor 
nanobubble induced scattering of the probe beam 
decreased its axial amplitude, resulting in a 
dip-shaped output signal of the photodetector moni-
toring the probe beam. Thus, the time response of the 
probe laser radiation to the transient scattering effect 
of the vapor nanobubbles was registered. This mode 
provided the monitoring of bubble growth and col-
lapse, delivering the bubble lifetime that characterizes 
its maximal diameter (30, 37, 38, 40, 42-44). The life-
time was measured as the duration of the bub-
ble-specific signal at half of the maximum amplitude 
level of the vapor nanobubble response. The vapor 
nanobubble lifetimes for each population of target 
and non-target cells were obtained by averaging data 
obtained from individual cells (20-30) over five dif-
ferent comparative experiments. In addition, we 
measured the probability of vapor nanobubble gen-
eration at a specific fluence of the excitation laser 
pulse. This allowed us to determine the bubble gen-
eration threshold fluence as the excitation laser flu-
ence that provides a vapor nanobubble generation 
probability of 0.5. 
Results 
Comparison of MUC1- and EGFR-targeted 
AuNPs in cells using three distinct methods 
Confocal Microscopy 
We targeted 60-nm AuNPs to this ectodomain 
using a mouse monoclonal antibody (214D4) raised 
against the PDTR residues within the tandem repeats 
of MUC1’s relatively large ectodomain. MUC1’s con-
stitutive endocytotic internalization (45, 46) allows for 
the formation of large 214D4-AuNPs clusters within 
endosomal vesicles, which are made visible using the 
reflected scattered light from a 633 nm source on 
confocal microscopy images. Following a one hour 
incubation in co-cultures containing MUC1 express-
ing (HES) and non-expressing (HS-5) human cell lines 
at 37ºC, the MUC1-directed particles demonstrated 
high specificity and accumulation in the targeted HES 
cells (Figure 1A, B), while low particle binding was 
observed in HS-5 cells. The potential for 
MUC1-targeted AuNPs to produce large intracellular 
clusters was compared to particles targeting the 
well-studied cell surface molecule, EGFR, using the 
monoclonal antibody C225. HES cells endogenously 
express both MUC1 and EGFR (Figure 1C). Confocal 
images were used to compare the size and distribu-
tion of clusters of both MUC1 and EGFR-targeted 
AuNPs throughout HES cells. The pixel intensity of 
the light reflected off AuNP clusters is proportional to 
the size of the cluster (36). MUC1-targeted AuNP 
clusters were 2.0, 2.3, and 2.7 times larger than the 
EGFR-targeted AuNP clusters at 2.5, 5.0, and 7.5 m, 
respectively from the apical cell surface (Figure 2A). 
Transmission Election Microscopy 
Analysis of transmission electron microscopic 
(TEM) images of HES cells incubated with either 
214D4- or C225-AuNPs for 12 hours show more and 
larger internalized clusters of the MUC1-targeted 
particles (Figure 2A, B). More than twice as many 
214D4-AuNP clusters, 39 compared to 18, were ob-
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served in the analysis of an equal number of TEM 
sections. The MUC1-targeted particles also aggregat-
ed into significantly larger clusters than the 
EGFR-targeted particles, 268.7 nm and 89.6 nm diam-
eters (p<0.001), respectively (Figure 2C). The largest 
214D4-AuNP clusters were over 500 nm in diameter 
with >25 individual AuNPs (each 60 nm diameter) 
visible in the ultrathin sections (70 nm), whereas most 
of the C225-AuNPs consisted of one or two visible 
particles.  
Vapor Nanobubbles 
Vapor nanobubbles are rapidly expanding and 
contracting transient vapor bubbles generated fol-
lowing exposure to one or more, short laser pulse 
directed towards intracellular AuNP clusters. The 
imaging potential of these bubbles is correlated to 
their size, which is proportional to their lifetime and 
can be tuned based on laser pulse fluence and AuNP 
cluster size; larger vapor nanobubbles correlate to 
larger NP clusters and are more capable of mechani-
cally disrupting the cell membrane (31). An example 
of this can be seen in HES cells incubated with 
214D4-AuNPs for one hour. Irradiation with a single 
laser pulse of 72 mJ/cm2 produced a small vapor 
nanobubble lasting 50 ns (Figure 3A-C), whereas, 
irradiation with 120 mJ/cm2 generates vapor nano-
bubble lasting 250 ns, (Figure 3D-F), large enough to 
visibly disrupt the cell membrane. 
The specificity and large clusters formed by the 
214D4-AuNPs make it an ideal vector for directed 
AuNP therapies. We compared the size and selectiv-
ity of vapor nanobubbles generated from MUC1- and 
EGFR-targeted AuNPs in HES (MUC1+/EGFR+) and 
HS-5 (MUC1-/EGFR+) cells. Both cell lines were in-
cubated with equal concentrations of individual tar-
geted particles or with a combination of both for one 
hour, and then individual cells were irradiated with a 
single laser pulse fluence of 42 mJ/cm2. We observed 
comparatively smaller vapor nanobubbles in the 
non-targeted HS-5 cells incubated with either 
214D4-AuNPs, C225-AuNPs, or a combination of both 
targeted particles. The vapor nanobubbles generated 
in HS-5 cells had average bubble lifetimes of 17.5, 29.2, 
and 49.0 ns, and restricted to a subset of cells, with 
bubble generation probabilities of 0.54, 0.65, and 0.65, 
respectively (Figure 4A, B). In MUC1-expressing HES 
cells, the probability of generating a bubble in a cell 
was 1.0 for all treatments. The average bubble lifetime 
in the HES cells using the 214D4-targeted AuNPs was 
150.8 ns, 73.7% larger than the 86.8 ns bubbles gener-
ated by C225-targeted AuNPs in the same cells 
(p<0.01). Combining both MUC1 and EGFR-targeted 
AuNPs generated even larger vapor nanobubbles, 
lasting 196.3 ns. Vapor nanobubbles generated from 
the MUC1-targeted AuNPs were also more cell spe-
cific than those formed around the EGFR-targeted 
particles, with lifetime ratios (HES/HS-5) of 8.6 and 
3.0, respectively. 
 
 
Figure 1: Targeting Specificity of MUC1-targeted AuNPs. Confocal microscopy images of fluorescently labeled cells incubated 
with antibody-AuNP conjugates (white dots) in reflective mode. Reflected light from the clusters of MUC1 targeted 214D4-AuNPs are 
visible in confocal microscope images as white dots on and within the HES cells but not the HS-5 cells. (A) Co-culture of HES (green) and 
HS-5 (orange) cells incubated with 214D4-AuNPs. (B) The fluorescent cell tracker channel is removed for clarity. (C) A western blot 
showing the relative MUC1 (214D4 and CT1 Abs) and EGFR expression in both cell lines. Scale bars = 20 m. 
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Figure 2: Endocytosis and Clustering of AuNPs. 214D4- and C225-AuNPs bind to either MUC1 or EGFR on the cell surface and 
are endocytosed to form intracellular clusters. (A) Analysis of confocal microscopy images show 214D4-AuNPs form significantly larger 
clusters at three depths from the apical cell surface of HES cells, 2.5, 5.0, and 7.5 m (1 m optical slices), following a 1-hour incubation 
with equal concentrations of targeted AuNPs. (B-D) TEM images depict intracellular (solid arrows) and extracellular (hollow arrow) 
AuNP clusters of various diameters in and around HES cells following a 12-hour incubation with equal concentrations of both targeted 
AuNPs. Each cluster consists of multiple 60 nm AuNPs (black dots). Clusters of MUC1-directed particles are significantly larger compared 
to EGFR-targeted particles (equal number of TEM sections analyzed). Error bars represent mean +/- SD. 
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Figure 3: Tunable vapor nanobubbles. HES cells incubated with 214D4-AuNPs were exposed to a short laser pulse. The leftmost 
panels (A and D) depict cells after AuNP incubation prior to laser irradiation. The center panels (B and E) show laser scattering off the 
vapor nanobubbles during their formation. The rightmost panels (C and F) show the effects of the vapor nanobubbles on the cells after 
laser irradiation. The higher laser pulse fluence (120 mJ/cm2) generated a large bubble, which destroyed the cell membrane (F). Scale bars 
= 10 m. 
 
 
Figure 4: Comparison of vapor nanobubbles incidence and size. Vapor nanobubbles were generated from individual and com-
bined treatments with MUC1-targeted (214D4) and EGFR-targeted (C225) AuNPs in both MUC1 and EGFR positive HES cells (blue) and 
MUC1 negative, EGFR positive HS-5 cells (tan). Cells were incubated with AuNPs for 1 hour, and then individual cells were irradiated with 
a single laser pulse (532 nm, 500 ps, 72 mJ/cm2). A) The probability of producing a bubble in a cell following irradiation. B) The size of the 
transient vapor nanobubbles is proportional to their lifetimes. Error bars represent mean +/- SD. 
 
Theranostics 2012, 2(8) 
 
http://www.thno.org 
784 
 
Figure 5: Size comparison of MUC1 and EGFR. Most cell surface proteins, including EGFR homodimers (green), extend 30-50 nm 
from the cell surface. In contrast, MUC1’s ectodomain (blue) is highly glycosylated (red) and rich in proline residues, giving it a highly 
extended structure, spanning 200-500 nm from the cell surface. Several AuNPs (orange spheres, 60 nm in diameter) are able to bind to 
tandem repeats in MUC1’s ectodomain.  Image drawn to scale. 
 
Discussion 
Mucins on the apical surface of normal mucosal 
epithelial cells serve both as a lubricant and a protec-
tive barrier. However in many cancer cells, MUC1 is 
overexpressed and the loss of cell polarity results in a 
distribution over the entire cell surface. The 
cell-surface receptor EGFR is also aberrantly 
over-expressed and distributed in many types of 
cancers (8) and has become a common target for na-
noparticle-based cancer therapies (reviewed in (13)). 
The current study compares the use of MUC1- and 
EGFR-targeted AuNPs for intracellular clustering and 
vapor nanobubble-based diagnostics in a high MUC1 
expressing human epithelial cell line. We demon-
strated that the MUC1-targeted particles (214D4) spe-
cifically bind to MUC1 expressing cells and form 
larger clusters than the EGFR-targeted particles (C225 
or cetuximab®) using three distinct methods: optical 
scattering, electron microscopy, and vapor nanobub-
ble sensing. Furthermore, we were able to effectively 
generate significantly larger vapor nanobubbles 
around the MUC1-targeted clusters than around the 
EGFR-targeted clusters. 
There are two potential explanations for the 
larger particle clustering and vapor nanobubbles 
formed in these MUC1 and EGFR expressing cells 
(Figure 1C). First, it seems highly possible that tar-
geting an epitope contained within the large number 
of tandem repeat motifs along MUC1’s ectodomain 
potentially permits accumulation of multiple AuNPs 
on each molecule, compared to a single AuNP bind-
ing to EGFR. MUC1’s ectodomain is rich in proline 
residues and in combination with a large number of 
O-linked oligosaccharides, give it a highly extended 
structure, spanning 200-500 nm from the cell surface 
(3). This potential accumulation of AuNPs per single 
MUC1 molecule permits cluster formation prior to 
endocytosis, which would result in larger aggregates. 
Second, MUC1’s large extended (200-500 nm) ecto-
domain and hydrated sugars create a steric and hy-
drophilic barrier to diffusing molecules in normal 
epithelia. However, in contrast most cell surface pro-
teins, including EGFR, extend only 30-50 nm from the 
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cell surface (3) (Figure 5). Thus, over-expression of 
MUC1, as occurs in many adenocarcinomas, effec-
tively obscures access of diffusing molecules to typical 
cell surface receptors, e.g., integrins and growth factor 
receptors such as EGFR. This same mechanism may 
account for the resistance of many adenocarcinoma 
cells that overexpress mucins to hydrophobic 
chemotherapeutic drugs (8). Although MUC1’s ecto-
domain creates a formidable barrier, these same fea-
tures make MUC1 an attractive target for nanoparticle 
based diagnostics and therapies. 
Reducing or removing the barrier imposed by 
MUC1 should increase the efficacy of AuNPs target-
ing smaller cell surface receptors. MUC1 siRNA 
knockdown experiments were performed in HES cells 
and reduced MUC1 levels by 75-90%; however, the 
effects on AuNP targeting were inconsistent. In most 
of the experiments endocytosis and clustering of 
214D4-AuNPs significantly increased over controls 
(data not shown). We speculate the dense population 
of MUC1 in untreated HES cells sterically hinders 
access to its own ectodomain, similar to its proposed 
effect on EGFR. As MUC1 is knocked down, the bar-
rier effects are reduced and 214D4-AuNPs gain access 
to the targeted epitope within the tandem repeat re-
gion. However, there appeared to be enough MUC1 
still present to obstruct access to EGFR, as there was 
no significant difference in C225-AuNP clustering in 
the siRNA treated cells (data not shown). Since MUC1 
co-localizes and binds with EGFR in various contexts 
in cancer cells (47, 48), it is also possible that this as-
sociation compromises access to EGFR. 
In the parameters of this study, MUC1 was 
shown to be a substantially better target than EGFR 
for AuNPs. However, EGFR is often used as a thera-
peutic target in many adenocarcinomas in which it is 
overexpressed. Glazer et al. compared both EGFR and 
MUC1 as candidates for AuNP mediated hyperther-
mic therapy using nonionizing radiofrequency radia-
tion (18). These researchers found EGFR targeted 
(C225) AuNPs were more effective than MUC1 tar-
geted (PAM4) particles at destroying pancreatic can-
cer xenografts in immune deficient mice. However, 
each targeting experiment was carried out on xeno-
grafts derived from different pancreatic cancer cell 
lines. EGFR-targeting experiments were performed on 
Panc-1 derived xenografts, which over express EGFR, 
but MUC1 is not detected (18); whereas, the 
MUC1-targeting experiments were performed on 
Capan-1 derived xenografts, which express both 
MUC1 and EGFR (18). Under these conditions, tar-
geting inhibition of the smaller cell surface receptor 
would not be observed. Conversely, the study we 
present compares both AuNP targets in a single cell 
line (HES), allowing us to examine the targeting inhi-
bition of smaller cell surface receptor like EGFR in the 
presence of MUC1. 
An important factor determining diagnostic ef-
ficacy is the choice of targeting antibody. Ideally, a 
targeting molecule will have high specificity to 
epitopes present on cancer cells with minimal affinity 
to those present in normal tissues. The monoclonal 
antibody used by Glazer et al., PAM4, is highly spe-
cific to a MUC1 glycoform found in pancreatic ade-
nocarcinoma and has little reactivity with pancreatitis 
and normal tissues (49, 50), with no reports of reac-
tivity with other cancer types. Whereas, this study 
demonstrated the efficacy of a MUC1-targeted ap-
proach using a well-characterized monoclonal anti-
body (214D4) with specificity to a mature glycoform 
of MUC1 and high affinity towards HES cells. Many 
tumor cells aberrantly over express underglycosylat-
ed forms of MUC1, which expose new core protein 
and carbohydrate antigens (51). These antigens can be 
used to further distinguish normal MUC1 expressing 
mucosa from cancerous tissue with a catalog of 
available of glycol form specific antibodies (51). 
Moreover, since tumors are heterogeneous in terms of 
their expression of various molecules, including cell 
surface components, targeting MUC1 in combination 
with other cancer associated transmembrane proteins 
or other membrane bound mucins (MUC4 and 
MUC16) may prove to be an effective therapeutic ap-
proach.  
MUC1’s steric and hydrophilic properties create 
an obstacle for many therapeutic approaches (1, 2, 8), 
especial when it is overexpressed. However, the na-
ture of this molecule offers promising opportunities to 
improve not only the efficacy of the AuNP-based 
therapies and diagnostic approaches described, but 
also conventional drug and siRNA delivery therapies 
(13). Additionally, MUC1 is also the predominant 
mucin in uterine epithelia and is believed to prevent 
embryo implantation in humans during the 
non-receptive phase (52, 53). Use of MUC1 targeted 
AuNPs for local cell therapeutics and diagnostics may 
prove to be a useful tool to improve implantation 
success during in vitro fertilization procedures.  
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